| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist | Phase 2 | AstraZeneca | <1 mi |
| A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers | N/A | Integra LifeSciences Corporation | <1 mi |
| Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control | N/A | Mayo Clinic | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | <1 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | <1 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | <1 mi |
| Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring | — | Abbott Diabetes Care | <1 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | <1 mi |
| Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC) | Phase 4 | Cellution Biologics | <1 mi |
| Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | <1 mi |
| Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families | N/A | Nemours Children's Clinic | <1 mi |
| Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD) | — | Mayo Clinic | <1 mi |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Phase 3 | NewAmsterdam Pharma | <1 mi |
| Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients | N/A | Mayo Clinic | <1 mi |
| CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance | N/A | Nemours Children's Clinic | <1 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | <1 mi |
| Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes | — | Nemours Children's Clinic | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Phase 2 | Vantage Biosciences Ltd | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | Phase 1/2 | GI Innovation, Inc. | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Phase 2 | Sun Pharmaceutical Industries Limited | <1 mi |
| Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | Phase 1 | Sun Pharmaceutical Industries Limited | <1 mi |
| FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | Phase 2 | Sanofi | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | Bayer | <1 mi |
| Capability Assessment for Diet and Activity (CADA) Model for Diabetes | — | University of Central Florida | <1 mi |
| Closed Loop and Education for Hypoglycemia Awareness Restoration | N/A | Milton S. Hershey Medical Center | <1 mi |
| Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes | N/A | AdventHealth Translational Research Institute | <1 mi |
| The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults | N/A | AdventHealth Translational Research Institute | <1 mi |
| Transdisciplinary Care for Young Adults With Type 1 Diabetes | N/A | Nemours Children's Clinic | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics | — | Milton S. Hershey Medical Center | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms | — | Milton S. Hershey Medical Center | <1 mi |
| Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | — | AdventHealth Translational Research Institute | <1 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | <1 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | <1 mi |
| Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis | N/A | AdventHealth Translational Research Institute | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | <1 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic Diabetes | <1 mi |
| Twiist Postmarket Surveillance Study for Type 1 Diabetes | — | Deka Research and Development | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| Study of Enhanced Programming Stimulation with the Enterra® Therapy System | N/A | Enterra Medical, Inc. | <1 mi |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Phase 3 | Eli Lilly and Company | <1 mi |
| Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes | N/A | UNC Lineberger Comprehensive Cancer Center | <1 mi |
| T1D Pregnancy & Me | — | Jaeb Center for Health Research | <1 mi |
| Pharmacist-led Continuous Glucose Monitoring | — | University of South Florida | <1 mi |
| A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes | N/A | First Institute of All Medicines | <1 mi |
| A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer | Phase 3 | Energenesis Biomedical Co., Ltd. | <1 mi |
| CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations | N/A | Capsicure, LLC | <1 mi |
| Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes. | N/A | Morehouse School of Medicine | <1 mi |
| ECHO Diabetes FQHC | — | University of Florida | <1 mi |
| Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers | N/A | LifeNet Health | <1 mi |
| Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Phase 1/2 | Creative Medical Technology Holdings Inc | <1 mi |
| Long Term Follow up of Recipients of Functional Islet Allografts | — | Rodolfo Alejandro | <1 mi |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Gilead Sciences | <1 mi |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes | Phase 1/2 | City of Hope Medical Center | <1 mi |
| Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye | Phase 1/2 | Midhat H. Abdulreda | <1 mi |
| Different Doses of Naronapride Vs. Placebo in Gastroparesis | Phase 2 | Dr. Falk Pharma GmbH | <1 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | <1 mi |
| Type 1 Diabetes Recurrence in Pancreas Transplants | — | University of Miami | <1 mi |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Ascletis Pharma (China) Co., Limited | <1 mi |
| Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | <1 mi |
| Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss | — | Rodolfo Alejandro | <1 mi |
| RESET System Pivotal Trial (Rev F) | N/A | Morphic Medical Inc. | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| CGM for the Early Detection and Management of Hyperglycemia in Pregnancy | N/A | Jaeb Center for Health Research | <1 mi |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Phase 1/2 | Alnylam Pharmaceuticals | <1 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | <1 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | <1 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | <1 mi |
| Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers | N/A | Tides Medical | <1 mi |
| Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. | Phase 4 | Royal Biologics | <1 mi |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Phase 2 | Jason Sperry | <1 mi |
| A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. | N/A | Molnlycke Health Care AB | <1 mi |
| Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss | N/A | Rodolfo Alejandro | <1 mi |
| A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D | Phase 1 | Alveus Therapeutics, Inc. | <1 mi |
| A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | Phase 1 | Eli Lilly and Company | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| Clinical Applications of Advanced Ophthalmic Imaging | N/A | University of Miami | <1 mi |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Phase 1/2 | Aulos Bioscience, Inc. | <1 mi |
| Trial to Assess Chelation Therapy in Critical Limb Ischemia | Phase 3 | Mt. Sinai Medical Center, Miami | 4 mi |
| NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers | Phase 1 | NOxy Health Products, LLC | 11 mi |
| A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL | Phase 4 | HealthTech Wound Care | 11 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 13 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | 14 mi |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | 16 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | 17 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | 17 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 17 mi |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Phase 2 | Eli Lilly and Company | 17 mi |
| A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers | Phase 4 | Applied Biologics, LLC | 17 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | 18 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) | N/A | Duke University | 18 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) | N/A | Duke University | 18 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Phase 3 | Kailera | 29 mi |
| Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing | N/A | Reprise Biomedical, Inc. | 31 mi |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Phase 2 | Walden Biosciences | 31 mi |
| Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care | N/A | Reprise Biomedical, Inc. | 31 mi |
| Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center | N/A | Medaxis, LLC | 32 mi |
| Neurologic Stem Cell Treatment Study | N/A | MD Stem Cells | 36 mi |
| A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | 48 mi |